Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a... Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate Susan L. Baldwin a , Valerie A. Reese a , Po-wei D. Huang a , Elyse A. Beebe a , Brendan K. Podell b , Steven G. Reed a , c and Rhea N. Coler a , c , d a Infectious Disease Research Institute, Seattle, Washington, USA b Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA c Department of Global Health, University of Washington, Seattle, Washington, USA d PAI Life Sciences, Inc., Seattle, Washington, USA D. W. Pascual , Editor ABSTRACT Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing family, which has been tested in small animal models in order to study its virulence and its induction of host immune responses following infection. This isolate causes death and extensive lung pathology in infected C57BL/6 mice, whereas lab-adapted strains, such as M. tuberculosis H37Rv, do not. The use of this clinically relevant isolate of M. tuberculosis increases the possibilities of assessing the long-lived efficacy of tuberculosis vaccines in a relatively inexpensive small animal model. This model will also allow for the use of knockout mouse strains to critically examine key immunological factors responsible for long-lived, vaccine-induced immunity in addition to vaccine-mediated prevention of pulmonary immunopathology. In this study, we show that the ID93/glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) tuberculosis vaccine candidate, currently in human clinical trials, is able to elicit protection against M. tuberculosis HN878 by reducing the bacterial burden in the lung and spleen and by preventing the extensive lung pathology induced by this pathogen in C57BL/6 mice. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate

Clinical and Vaccine Immunology , Volume 23 (2): 137 – Feb 1, 2016

Abstract

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate Susan L. Baldwin a , Valerie A. Reese a , Po-wei D. Huang a , Elyse A. Beebe a , Brendan K. Podell b , Steven G. Reed a , c and Rhea N. Coler a , c , d a Infectious Disease Research Institute, Seattle, Washington, USA b Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA c Department of Global Health, University of Washington, Seattle, Washington, USA d PAI Life Sciences, Inc., Seattle, Washington, USA D. W. Pascual , Editor ABSTRACT Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing family, which has been tested in small animal models in order to study its virulence and its induction of host immune responses following infection. This isolate causes death and extensive lung pathology in infected C57BL/6 mice, whereas lab-adapted strains, such as M. tuberculosis H37Rv, do not. The use of this clinically relevant isolate of M. tuberculosis increases the possibilities of assessing the long-lived efficacy of tuberculosis vaccines in a relatively inexpensive small animal model. This model will also allow for the use of knockout mouse strains to critically examine key immunological factors responsible for long-lived, vaccine-induced immunity in addition to vaccine-mediated prevention of pulmonary immunopathology. In this study, we show that the ID93/glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) tuberculosis vaccine candidate, currently in human clinical trials, is able to elicit protection against M. tuberculosis HN878 by reducing the bacterial burden in the lung and spleen and by preventing the extensive lung pathology induced by this pathogen in C57BL/6 mice.

Loading next page...
 
/lp/american-society-for-microbiology/protection-and-long-lived-immunity-induced-by-the-id93-gla-se-vaccine-f2kK1GNwXA

References (67)

Publisher
American Society For Microbiology
Copyright
Copyright © 2016 by the American society for Microbiology.
ISSN
1556-6811
eISSN
1556-679X
DOI
10.1128/CVI.00458-15
pmid
26656121
Publisher site
See Article on Publisher Site

Abstract

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate Susan L. Baldwin a , Valerie A. Reese a , Po-wei D. Huang a , Elyse A. Beebe a , Brendan K. Podell b , Steven G. Reed a , c and Rhea N. Coler a , c , d a Infectious Disease Research Institute, Seattle, Washington, USA b Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA c Department of Global Health, University of Washington, Seattle, Washington, USA d PAI Life Sciences, Inc., Seattle, Washington, USA D. W. Pascual , Editor ABSTRACT Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing family, which has been tested in small animal models in order to study its virulence and its induction of host immune responses following infection. This isolate causes death and extensive lung pathology in infected C57BL/6 mice, whereas lab-adapted strains, such as M. tuberculosis H37Rv, do not. The use of this clinically relevant isolate of M. tuberculosis increases the possibilities of assessing the long-lived efficacy of tuberculosis vaccines in a relatively inexpensive small animal model. This model will also allow for the use of knockout mouse strains to critically examine key immunological factors responsible for long-lived, vaccine-induced immunity in addition to vaccine-mediated prevention of pulmonary immunopathology. In this study, we show that the ID93/glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) tuberculosis vaccine candidate, currently in human clinical trials, is able to elicit protection against M. tuberculosis HN878 by reducing the bacterial burden in the lung and spleen and by preventing the extensive lung pathology induced by this pathogen in C57BL/6 mice.

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: Feb 1, 2016

There are no references for this article.